Changchun Bcht Biotechnology Co. Class ASSE: 688276

Announcement on Voluntary Disclosure of Approval for Clinical Trial Application of Type II Herpes Simplex Virus mRNA Vaccine

· Issued by Changchun Bcht Biotechnology Co. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of Approval for Clinical Trial Application of Type II Herpes Simplex Virus mRNA Vaccine

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment